Baxter International and Halozyme Therapeutics obtained approval from the European Commission to market HyQvia as a replacement treatment for adults with primary and secondary immunodeficiency disorders. The treatment, a combination of human normal immunoglobulin and recombinant human hyaluronidase, is intended to be taken once every three to four weeks.
Baxter/Halozyme's HyQvia wins EU nod for immunodeficiencies
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|